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OBJECTIVES: Decision analytic models used in cost-effectiveness analysis often
rely upon long-term survival data from observational studies for which patient-
level data are not available. Analysts may therefore be required to digitally extract
survival data from published Kaplan-Meier plots and fit parametric survival curves,
in order to provide estimates of time until an event or a per-cycle probability of an
event occurring. Methods used in practice include minimising a sum of squared
residuals statistic (using Microsoft Excel Solver) in order to estimate desired pa-
rameters for a given distribution. A technique recently published by Guyot et al
provides a methodology for reconstructing a patient-level dataset from published
Kaplan-Meier plots, using the tabulated numbers at risk to incorporate censoring.
An alternative reconstructing methodology which does not account for censoring
is also explored. We sought to establish the accuracy of these methods.METHODS:
The techniques described were tested on a published dataset (Gehan). Patient-level
datasets were reconstructed based on the digitised curves. Results of survival mod-
els fitted using these techniques are presented for comparison against models
fitted using the original data. RESULTS: Median survival times using a Weibull
regression on the original dataset was 7.2 and 25.7 months for the placebo and
treatment arms, respectively. Using the minimisation of squared residuals ap-
proach resulted in median times of 6.1 and 25.0 months. The reconstructed patient-
level approach incorporating censoring yielded median times of 7.1 and 28.9
months, whilst the alternative technique (without censoring) resulted in median
times of 7.1 and 27.6 months. CONCLUSIONS: The reconstructed patient-level da-
tasets can be interrogated as per patient-level survival data, allowing diagnostic
statistics such as the Akaike Information Criterion to be estimated and plots of
log-cumulative hazard to be generated, which aid the analyst in selecting appro-
priate distributions and assumptions. It is therefore suggested that these tech-
niques become the preferred methods.
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OBJECTIVES: The Cox proportional hazards (PH) model is commonly used to de-
scribe time-to-event data in CEAs. Although this methodology has many advan-
tages, it requires proportional hazards, a strong assumption that is rarely checked
and hardly verifiable in case of lack of individual patient data (IPD). Time-to-event
outcomes are usually reported in clinical studies by Kaplan-Meier plots with me-
dian time-to-events or hazard ratios. In CEAs, the common practice is to digitalize
the published Kaplan-Maier graphs and fit parametric model to predict the treat-
ment effects. However all these data are insufficient to get unambiguous and ob-
jective results of conventional PH assumption tests. Our aim was to present two
alternative algorithms of how PH assumption may be checked based on data re-
ported in clinical studies. METHODS: The first method applies the algorithm pro-
posed in Guyot 2012 (BMC Medical Research Methodology 2012, 12:9) which closely
approximates the original Kaplan-Meier curves from published graphs. Advanced,
analytical techniques were adopted to estimated IPD to check PH assumption. The
second algorithm utilizes the Weibull model fitted to digitalized Kaplan-Maier
data. Statistical tests for comparison of the fitted shape coefficients were applied to
verify PH assumption (in Weibull model if difference between shape coefficients is
statistically insignificant PH assumption is accepted). The accuracy of both algo-
rithms was assessed in theoretical computer simulations and by comparing results
of published IPD analysis and discussed algorithms on empirical data from trials
systematically identified in Medline. RESULTS: The validation exercise established
there was agreement in results of PH testing by IPD analysis and proposed algo-
rithms. The inconsistence areas were specified. CONCLUSIONS: The algorithms
are a reliable tools for testing PH assumption of time-to-event data in case of lack of
IPD. It is recommended that all CEAs where survival analysis was included should
test PH assumption using at least one of proposed methods.
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OBJECTIVES: Decision-analytic cost-effectiveness (CE) models combine many dif-
ferent parameters, which are often obtained after indirect meta-analysis. The
choice of method may affect CE estimates. We aimed to compare different methods
of indirect meta-analysis, especially with respect to health economic (HE) out-
comes as the costs per QALY. METHODS: A reference patient population
(N50,000) was simulated, from which sets of trials were drawn, comparing two of
four fictitious interventions. Heterogeneity was added in pre-specidifed scenarios
by drawing from subpopulations. Trial-specific parameter estimates were com-
bined using Bucher’s direct and indirect comparisons, and the mixed treatment
comparison (MTC) methods by Song, Puhan and Lu/Ades (fixed and random ef-
fects). Pooled parameters were entered into a HE Markov model. We studied
whether differences were systematic by repeating the sampling and indirect meta-
analysis 1,000 times. Estimated parameters and HE outcomes were compared using
coverage, bias, mean absolute deviation (MAD) and statistical power. RESULTS:
Bucher’s methods are outperformed by the MTC methods, generally overestimat-
ing uncertainty and having a relatively large MAD. HE outcomes for Song have low
MAD and bias, but uncertainty is overestimated. Puhan’s method does not overes-
timate uncertainty and generally is the closest to the true parameter value, regard-
less of heterogeneity. Both lead to the least amount of uncertainty reflected in the
CE acceptability curve (CEAC). Lu/Ades fixed effects performs slightly worse than
Puhan and Song in terms of bias and MAD. Uncertainty is generally overestimated,
regardless of heterogeneity. It is also slightly less certain in the CEAC. Only with
considerable heterogeneity does the Lu/Ades random effects model have the low-
est bias. It still shows large MAD and uncertainty is almost always overestimated.
CONCLUSIONS: Regardless of heterogeneity, combining direct and indirect evi-
dence improves results. HE outcomes produced with Puhan’s method have the best
statistical properties.
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OBJECTIVES: Predicting the price change percentages and timings of drugs is im-
portant to policy makers, pharmaceutical companies, and even investment firms.
As a case study, we utilize a set of oncology drugs in the US and apply hazard
models to perform the predictions. METHODS: Using data from First DataBank
(2003-2012), we have a panel of ex-factory drug prices for drug packs for 18 brand
names. We convert the data into survival time data by calculating the time dura-
tion between each price change, which results in a total of 200 price increases and
38 censored outcomes. In our hazard models, we include the FDA approval date for
each drug as an exogenous variable to answer the following questions: 1) how is the
percentage change in price related to the time since the last price change and the
time since FDA approval, and 2) does the probability of a price change depend on
the time since FDA approval? We use Cox Proportional Hazard models for
prediction. RESULTS: The average “event” is a price increase of 5%. For percentage
changes in price, we find that for each additional month of constant price, the
subsequent price increase drops by 0.08%. For a second order effect, we find that
the negative effect of time since last price change is decreasing. Also, time since
FDA approval has a large and significant effect: for each additional month since
FDA approval, the subsequent price increase drops by 0.03%. The average duration
between events is 8.8 months. The Cox model shows that for each additional
month since FDA approval, the “risk” of a price increase increases by 0.7%. Simi-
larly, there is a second order effect showing this risk diminishing over time.
CONCLUSIONS: Hazard models can predict the timing and percentage of price
changes in oncology drugs in the United States.
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OBJECTIVES: The Syreon type 2 diabetes model projects outcomes for populations
over time with taking into account baseline patient characteristics, history of com-
plications, changes in physiological parameters, diabetes treatment and manage-
ment strategies, and screening programs. The objective of this study was to eval-
uate the internal validity of the health economic model and confirm the predictive
accuracy of the model variables. METHODS: The internal validation was designed
according to published methodological standards. A total of 71 second- (internal)
order validation analyses were performed across a range of complications and
model outcomes for each submodel (ischemic heart disease, retinopathy, hypogly-
caemia, nephropathy, neuropathy, foot ulcer, peripherial vascular disease, stroke
and ketoacidosis). Published studies were reproduced by recreating cohorts ac-
cording to important patient characteristics, treatment patterns and management
strategies. The model simulated the progress of the cohorts until the published
studies’ time horizon. The published and simulated incidence rates were then
compared and the validation analysis was considered successful, if the published
incidence rates fell within the confidence interval of the simulated incidence rates.
RESULTS: First results show that the model simulations were generally close to
published outcomes. No significant differences between the simulated and the
published incidence rates and life expectancy were observed. The average absolute
difference in the case of transition probability parameters was 0,056%. The model
predicted an average absolute difference of 0.025% in life expectancy between the
published data simulated data. A correlation plot of published versus simulated
results showed a trend line with a gradient of close to 1. CONCLUSIONS: Based on
the first results the Syreon health economic model correctly replicates the devel-
opment and progression of diabetes and can be used to evaluate the cost-effective-
ness of potential diabetes prevention and treatment programs. External validation
is needed to further confirm the predictive accuracy and reliability of the model.
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OBJECTIVES: To compare the efficacy of two treatments in mCRPC using alterna-
tive approaches to indirect treatment comparisons (ITCs). METHODS: The TROPIC
and COU-AA-301 trials demonstrated that cabazitaxelprednisone (CbzP) and
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